Drug Profile
AL 2846
Alternative Names: AL-2846Latest Information Update: 03 Jul 2023
Price :
$50
*
At a glance
- Originator Advenchen Laboratories
- Developer Advenchen Laboratories; Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Lung cancer; Ovarian cancer
- Phase I/II Colorectal cancer; Neurofibromatosis 1; Pancreatic cancer; Thyroid cancer
- Phase I Solid tumours
Most Recent Events
- 08 Jun 2023 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy, Inoperable/Unresectable, Recurrent) in China (PO) (NCT05922345)
- 24 Feb 2023 Phase-I/II clinical trials in Thyroid cancer (Second-line therapy or greater) in China (PO) (NCT05745363)
- 15 Feb 2023 Phase-II clinical trials in Lung cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05815862)